The article from Gizmodo discusses the promising future of obesity treatments, focusing on the potential of emerging drugs that could surpass current standards like Ozempic and Wegovy. A review from McGill University highlights the effectiveness of GLP-1 drugs, particularly semaglutide, but points to newer compounds such as retatrutide, which showed better results in weight loss during clinical trials. While current treatments have proven effective, researchers are optimistic about future medications that could offer even greater benefits. However, issues such as side effects, pricing, and insurance coverage remain significant challenges.

Key Points:

• Ozempic (semaglutide) and Wegovy signify the onset of a new era in obesity treatment.
• Retatrutide, a new drug under development, has shown potential for a 22% weight loss over 48 weeks in trials.
• Tirzepatide, a dual-agonist drug, has also shown impressive results, with participants losing up to 20% of their weight.
• A variety of other drugs and combinations, like amycretin and survodutide, are in trials and may offer better outcomes.
• Current obesity drugs are generally safe but can cause gastrointestinal side effects and have a high cost (approx. $1,000/month).
• The growing demand for these medications has led to a rise in grey and black market sales.
• Experts hope that the introduction of more drugs will address issues of cost and insurance coverage.
  Link to Article